Publications by authors named "L Khalifa"

Left ventricular assist devices (LVAD) are increasingly used for management of heart failure; infection remains a frequent complication. Phage therapy has been successful in a variety of antibiotic refractory infections and is of interest in treating LVAD infections. We performed a retrospective review of four patients that underwent five separate courses of intravenous (IV) phage therapy with concomitant antibiotic for treatment of endovascular LVAD infection.

View Article and Find Full Text PDF

Scarcity of freshwater for agriculture has led to increased utilization of treated wastewater (TWW), establishing it as a significant and reliable source of irrigation water. However, years of research indicate that if not managed adequately, TWW may deleteriously affect soil functioning and plant productivity, and pose a hazard to human and environmental health. This review leverages the experience of researchers, stakeholders, and policymakers from Israel, the United-States, and Europe to present a holistic, multidisciplinary perspective on maximizing the benefits from municipal TWW use for irrigation.

View Article and Find Full Text PDF

Urban wastewater treatment plants (UWTPs) are essential for reducing the pollutants load and protecting water bodies. However, wastewater catchment areas and UWTPs emit continuously antibiotic resistant bacteria (ARB) and antibiotic resistance genes (ARGs), with recognized impacts on the downstream environments. Recently, the European Commission recommended to monitor antibiotic resistance in UWTPs serving more than 100 000 population equivalents.

View Article and Find Full Text PDF
Article Synopsis
  • A recent study examined the use of PASA16 phage therapy in 16 patients with stubborn Pseudomonas aeruginosa infections, highlighting the largest compassionate-use series of its kind.
  • The phages were administered either intravenously or topically, showing good results in 13 out of 15 cases, with only minor side effects reported.
  • The findings suggest that combining PASA16 with traditional antibiotics is a promising option for patients who haven't responded to standard treatments, paving the way for future clinical trials.
View Article and Find Full Text PDF